中海達(300177.SZ):收到業績承諾補償款1011.561萬元及相關賠付
格隆匯9月21日丨中海達(300177.SZ)公佈,截止本公告日,公司已收到西安靈境科技有限公司(以下簡稱“靈境科技”)股東徐建榮、崔西寧剩餘補償款及補償利息合計1011.561萬元。此外,根據公司與靈境科技股東長興靈境企業管理諮詢合夥企業(有限合夥)(以下簡稱“長興靈境”)、徐建榮、崔西寧各方於2019年12月20日簽署的《股權轉讓協議》相關約定,長興靈境、徐建榮、崔西寧合計應向公司賠付8.3478%的靈境科技股權,該股權賠付已執行完畢。截止本公告日,公司於2017年和2019年對靈境科技涉及的股份收購所對應的本階段的補償與賠付事宜已全部執行完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.